NCT05322408
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have not progressed on at least 2 prior lines of therapy given either in the recurrent or metastatic setting; Patients with known or suspected untreated central nervous system (CNS) metastases; Patients with prior exposure to TGF-B antagonist or IL-15 or analogs
https://ClinicalTrials.gov/show/NCT05322408